Endovascular treatment of posterior circulation aneurysms with flow diverters with hydrophilic polymer coating in patients receiving prasugrel single antiplatelet therapy: a multicenter case series presenting complication and occlusion rates.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 40541401.
- Also identified by DOI 10.1136/jnis-2025-023617 and PMC identifier 13217117.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The present study reports a multicenter experience of using hydrophilic polymer-coated (HPC) flow diverters (FDs) with prasugrel single antiplatelet therapy (SAPT) to treat posterior circulation aneurysms (PCAs). A prospectively maintained database was retrospectively reviewed to identify all cases of intracranial PCA treated with HPC-coated FDs under SAPT (prasugrel). The clinical presentation and outcomes, periprocedural and postprocedural complications, and degree of occlusion at follow-up (FU) were evaluated. A total of 74 patients were treated (45.9% female). Ischemic complications were experienced by two patients (2.7%) and were dependent on the use of FDs. No cases of aneurysm rupture or hemorrhagic complications related to antiplatelet therapy or the FD treatment were recorded. The rate of complete occlusion was 77.9% in the early FU period (3-6 months) and 90.3% in the initial 12-month period. In this single-arm retrospective study, HPC-coated FDs with prasugrel SAPT were associated with high safety in the treatment of ruptured and unruptured PCA and high occlusion rates at early- and mid-term FU.
Medical subject headings
- Prasugrel Hydrochloride
- Platelet Aggregation Inhibitors
- Intracranial Aneurysm
- Endovascular Procedures
- Polymers